A Phase I Trial Assessing the Feasibility of Romidepsin Combined With Brentuximab Vedotin for Patients Requiring Systemic Therapy for Cutaneous T-cell Lymphoma

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 01 Mar 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Brentuximab vedotin (Primary) ; Romidepsin (Primary)
Indications Anaplastic large cell lymphoma; Cutaneous T-cell lymphoma; Lymphoproliferative disorders; Mycosis fungoides; Sezary syndrome
Focus Adverse reactions

09 Mar 2023 Planned End Date changed from 1 Jul 2023 to 1 Dec 2024.
09 Mar 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2023.
09 Mar 2023 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com